Short answer
Nuvectis Pharma, Inc. (NVCT) filed an 8-K current report with the SEC on June 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). $100 million gross equity offering: 5,000,000 shares at $20.00 each.
Nuvectis Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $100 million gross equity offering: 5,000,000 shares at $20.00 each
- Approximately $93 million net proceeds, increasing to approximately $107 million if the option is fully exercised
- Underwriters can purchase 750,000 additional shares within 30 days, creating potential further dilution
- Expected July 1, 2026 closing, subject to customary conditions
- Capital raise strengthens funding capacity but expands common-stock share count for existing holders
Item 8.01 · Other Events
- Nuvectis launched and priced a securities offering on June 29, 2026
- Offering likely creates potential dilution or financing proceeds for NVCT shareholders
- Pricing, security type, size, and use of proceeds require review of Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.2
- Proposed underwritten public offering of common stock, creating potential dilution for existing shareholders
- Underwriters granted 30-day option for up to 15% additional shares, potentially increasing dilution
- Offering size, price, and completion remain subject to market conditions and have not been finalized
- Proceeds intended for NXP100, NXP200, NXP900 development, hiring, capital expenditures, and general corporate purposes
- Capital raise supports pipeline advancement but signals ongoing funding needs typical of a clinical-stage biotechnology company
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvectis Pharma, Inc. 8-K filings
Get the next NVCT 8-K as it lands
Follow NVCT for push alerts, or ask the research agent what this filing means.